Antiviral Drugs - Guatemala | Statista Market Forecast

The Antiviral Drugs market in Guatemala is anticipated to achieve a revenue of US$17.15m in 2024.
This market is forecasted to exhibit a compound annual growth rate (CAGR 2024-2029) of 2.20%, leading to a market volume of US$19.12m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$30.64bn in 2024.
The demand for antiviral drugs in Guatemala has surged due to the increasing prevalence of viral infections and the need for effective treatment options.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The demand for Antiviral Drugs in Guatemala has been on the rise in recent years, driven by various factors that have contributed to the growth of the market.

Customer preferences: Guatemalan customers have shown a growing preference for Antiviral Drugs due to the increasing incidence of viral infections in the country. The rise in the number of cases of diseases such as hepatitis, HIV, and influenza has led to an increased demand for Antiviral Drugs as a means of treatment.

Trends in the market: The trend in the Antiviral Drugs market in Guatemala is towards the development of more effective and affordable drugs. Pharmaceutical companies are investing heavily in research and development to come up with new and improved drugs that can effectively treat viral infections. The market is also witnessing an increase in the availability of generic drugs, which are more affordable and accessible to the general population.

Local special circumstances: Guatemala has a high incidence of viral infections, which has contributed to the growth of the Antiviral Drugs market. The lack of proper sanitation and healthcare facilities in many parts of the country has led to the spread of diseases, making Antiviral Drugs a necessity for many people.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in Guatemala is also influenced by macroeconomic factors such as the country's GDP growth, government policies, and healthcare spending. The government's efforts to improve healthcare infrastructure and increase healthcare spending have contributed to the growth of the market. Additionally, the country's growing middle class and increasing disposable income have led to an increase in demand for healthcare services, including Antiviral Drugs.In conclusion, the Antiviral Drugs market in Guatemala is growing due to the increasing incidence of viral infections, the trend towards the development of more effective and affordable drugs, local special circumstances, and underlying macroeconomic factors. The market is expected to continue growing in the coming years, driven by these factors and the increasing demand for healthcare services in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.